All you need to get started with ETF selection and analysis. Create your account now →
Help us improve your experience. Please confirm your investor type:
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
CURE ETF · Global X S&P Biotech ETF
Performance & flows
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +5.36%  | +2.52% | +40.65% | +46.67% | +2.42%  | -2.05% | -2.05% | -0.23%  | |
| Flows |
Key fund info
Essentials
Enterprise
Similar ETFs in your region
Advertisement
Risk profile
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +2.52% | +40.65% | +46.67% | +2.42%  |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Exposure
Sustainability
ESG Consensus® by Conser
Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about CURE ETF's sustainability, based on their methodology.
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
CURE’s has a Final Sustainability Grade of either A+, A, or A-.
Issuer
| AuM | ||
|---|---|---|
PAVE | Global X U.S. Infrastructure Development ETF | €11.4B |
AIQ | Global X Artificial Intelligence & Technology ETF | €7.48B |
QYLD | Global X Nasdaq 100 Covered Call ETF | €7.13B |
SHLD | Global X Defense Tech ETF | €6.87B |
URA | Global X Uranium ETF | €6.6B |
Frequently asked questions about CURE
What does Global X S&P Biotech ETF, CURE, invest in?
CURE is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.
Which benchmark or index does CURE replicate?
CURE tracks the S&P Biotechnology Select Industry Net Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of CURE?
CURE carries a total expense ratio (TER) of 0.45%, indicating the annual cost for holding the fund.
When was CURE launched?
CURE was introduced to the market on November 8, 2018. It trades on Australia
Who is the ETF issuer of CURE?
Global X S&P Biotech ETF, CURE, is provided by Global X. Learn more about Global X here.
What is the current assets under management (AUM) of CURE?
CURE oversees €25M in assets as of April 30, 2026.
How has CURE performed lately?
Based on data from April 30, 2026, CURE returned 5.36% over the past month, 2.52% over the last three months and -0.23% year-to-date.
What are the latest inflows or outflows for CURE?
As of April 30, 2026, CURE recorded net flows of -€715K year-to-date.
Does CURE distribute dividends?
CURE follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of CURE?
As of March 31, 2026, CURE has significant geographic allocations in USA, Ireland and Switzerland.
In which sector or theme does CURE invest in?
As of March 31, 2026, CURE focuses largely on Health Care.
How many securities does CURE hold and how diversified is it?
As of March 31, 2026, CURE holds 147 positions in its portfolio, with 18.54% of assets concentrated in its top 15 holdings.
What are the main positions in CURE?
As of March 31, 2026, CURE top three holdings include TG THERAPEUTICS, PROTAGONIST THERAPEUTICS INC and MADRIGAL PHARMACEUTICALS INC.
What is the base currency of CURE?
The base currency of CURE is AUD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
